Benjamin Burnett
Stock Analyst at Wells Fargo
(3.81)
# 669
Out of 5,148 analysts
96
Total ratings
55.56%
Success rate
8.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Maintains: Overweight | $34 → $30 | $20.23 | +48.29% | 1 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $37 → $43 | $30.10 | +42.86% | 4 | Feb 26, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $193 → $202 | $163.89 | +23.25% | 4 | Feb 24, 2026 | |
| INSM Insmed | Maintains: Overweight | $234 → $208 | $149.33 | +39.29% | 2 | Feb 20, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $26.86 | +30.31% | 3 | Nov 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.48 | +102.70% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $60.14 | -18.52% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $113.79 | +7.22% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $28.46 | +142.45% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $32.20 | +111.18% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $4.4 → $4.6 | $2.78 | +65.47% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $5.42 | +960.89% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $4.20 | +18,471.43% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $49 | $43.23 | +13.35% | 4 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $3.28 | +113.41% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $423 → $466 | $503.90 | -7.52% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $282 → $305 | $336.75 | -9.43% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $86 | $68.19 | +26.12% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $27 | $13.93 | +93.83% | 3 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $43 | $29.03 | +48.12% | 1 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $23.39 | +92.39% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $6.02 | +49.50% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $14.19 | +62.09% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $102.02 | -37.27% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $66.62 | +41.10% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.79 | +163.85% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.86 | +547.67% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $68.98 | +421.89% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.43 | +3,601.13% | 1 | Jan 6, 2021 |
Amphastar Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $34 → $30
Current: $20.23
Upside: +48.29%
Alkermes
Feb 26, 2026
Maintains: Overweight
Price Target: $37 → $43
Current: $30.10
Upside: +42.86%
Axsome Therapeutics
Feb 24, 2026
Maintains: Overweight
Price Target: $193 → $202
Current: $163.89
Upside: +23.25%
Insmed
Feb 20, 2026
Maintains: Overweight
Price Target: $234 → $208
Current: $149.33
Upside: +39.29%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $26.86
Upside: +30.31%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.48
Upside: +102.70%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $60.14
Upside: -18.52%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $113.79
Upside: +7.22%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $28.46
Upside: +142.45%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $32.20
Upside: +111.18%
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $2.78
Upside: +65.47%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $5.42
Upside: +960.89%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $4.20
Upside: +18,471.43%
Feb 27, 2026
Maintains: Overweight
Price Target: $48 → $49
Current: $43.23
Upside: +13.35%
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $7
Current: $3.28
Upside: +113.41%
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $423 → $466
Current: $503.90
Upside: -7.52%
Feb 20, 2026
Maintains: Equal-Weight
Price Target: $282 → $305
Current: $336.75
Upside: -9.43%
Feb 20, 2026
Maintains: Overweight
Price Target: $93 → $86
Current: $68.19
Upside: +26.12%
Feb 12, 2026
Maintains: Overweight
Price Target: $29 → $27
Current: $13.93
Upside: +93.83%
Feb 2, 2026
Initiates: Overweight
Price Target: $43
Current: $29.03
Upside: +48.12%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $23.39
Upside: +92.39%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $6.02
Upside: +49.50%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $14.19
Upside: +62.09%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $102.02
Upside: -37.27%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $66.62
Upside: +41.10%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.79
Upside: +163.85%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $3.86
Upside: +547.67%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $68.98
Upside: +421.89%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.43
Upside: +3,601.13%